The current landscape of targeted clinical trials in non-WNT/non-SHH medulloblastoma

Medulloblastoma is an embryonal pediatric brain tumor and can be divided into at least four molecularly defined groups. The category non-WNT/non-SHH medulloblastoma summarizes medulloblastoma groups 3 and 4 and is characterized by considerable genetic and clinical heterogeneity. New therapeutic stra...

Full description

Saved in:
Bibliographic Details
Main Authors: Ghasemi, David R. (Author) , Fleischhack, Gudrun (Author) , Milde, Till (Author) , Pajtler, Kristian Wilfried (Author)
Format: Article (Journal)
Language:English
Published: 28 January 2022
In: Cancers
Year: 2022, Volume: 14, Issue: 3, Pages: 1-22
ISSN:2072-6694
DOI:10.3390/cancers14030679
Online Access:Verlag, lizenzpflichtig, Volltext: https://doi.org/10.3390/cancers14030679
Verlag, lizenzpflichtig, Volltext: https://www.mdpi.com/2072-6694/14/3/679
Get full text
Author Notes:David R. Ghasemi, Gudrun Fleischhack, Till Milde and Kristian W. Pajtler

MARC

LEADER 00000caa a2200000 c 4500
001 1797754092
003 DE-627
005 20230428015057.0
007 cr uuu---uuuuu
008 220406s2022 xx |||||o 00| ||eng c
024 7 |a 10.3390/cancers14030679  |2 doi 
035 |a (DE-627)1797754092 
035 |a (DE-599)KXP1797754092 
035 |a (OCoLC)1341458244 
040 |a DE-627  |b ger  |c DE-627  |e rda 
041 |a eng 
084 |a 33  |2 sdnb 
100 1 |a Ghasemi, David R.  |e VerfasserIn  |0 (DE-588)1209581906  |0 (DE-627)1697246699  |4 aut 
245 1 4 |a The current landscape of targeted clinical trials in non-WNT/non-SHH medulloblastoma  |c David R. Ghasemi, Gudrun Fleischhack, Till Milde and Kristian W. Pajtler 
246 3 0 |a Medulloblastoma systemic therapy clinical trials and their foundations 
264 1 |c 28 January 2022 
300 |a 22 
336 |a Text  |b txt  |2 rdacontent 
337 |a Computermedien  |b c  |2 rdamedia 
338 |a Online-Ressource  |b cr  |2 rdacarrier 
500 |a This article belongs to the Special issue: Medulloblastoma systemic therapy clinical trials and their foundations 
500 |a Gesehen am 06.04.2022 
520 |a Medulloblastoma is an embryonal pediatric brain tumor and can be divided into at least four molecularly defined groups. The category non-WNT/non-SHH medulloblastoma summarizes medulloblastoma groups 3 and 4 and is characterized by considerable genetic and clinical heterogeneity. New therapeutic strategies are needed to increase survival rates and to reduce treatment-related toxicity. We performed a noncomprehensive targeted review of the current clinical trial landscape and literature to summarize innovative treatment options for non-WNT/non-SHH medulloblastoma. A multitude of new drugs is currently evaluated in trials for which non-WNT/non-SHH patients are eligible, for instance immunotherapy, kinase inhibitors, and drugs targeting the epigenome. However, the majority of these trials is not restricted to medulloblastoma and lacks molecular classification. Whereas many new molecular targets have been identified in the last decade, which are currently tested in clinical trials, several challenges remain on the way to reach a new therapeutic strategy for non-WNT/non-SHH medulloblastoma. These include the severe lack of faithful preclinical models and predictive biomarkers, the question on how to stratify patients for clinical trials, and the relative lack of studies that recruit large, homogeneous patient collectives. Innovative trial designs and international collaboration will be a key to eventually overcome these obstacles. 
650 4 |a group 3 medulloblastoma 
650 4 |a group 4 medulloblastoma 
650 4 |a molecularly guided trials 
650 4 |a non-WNT/non-SHH medulloblastoma 
650 4 |a precision medicine 
700 1 |a Fleischhack, Gudrun  |e VerfasserIn  |4 aut 
700 1 |a Milde, Till  |d 1973-  |e VerfasserIn  |0 (DE-588)1038311837  |0 (DE-627)75711234X  |0 (DE-576)39229334X  |4 aut 
700 1 |a Pajtler, Kristian Wilfried  |d 1980-  |e VerfasserIn  |0 (DE-588)1012877264  |0 (DE-627)662768558  |0 (DE-576)346086256  |4 aut 
773 0 8 |i Enthalten in  |t Cancers  |d Basel : MDPI, 2009  |g 14(2022), 3, Special issue, Artikel-ID 679, Seite 1-22  |h Online-Ressource  |w (DE-627)614095670  |w (DE-600)2527080-1  |w (DE-576)313958548  |x 2072-6694  |7 nnas  |a The current landscape of targeted clinical trials in non-WNT/non-SHH medulloblastoma 
773 1 8 |g volume:14  |g year:2022  |g number:3  |g supplement:Special issue  |g elocationid:679  |g pages:1-22  |g extent:22  |a The current landscape of targeted clinical trials in non-WNT/non-SHH medulloblastoma 
856 4 0 |u https://doi.org/10.3390/cancers14030679  |x Verlag  |x Resolving-System  |z lizenzpflichtig  |3 Volltext 
856 4 0 |u https://www.mdpi.com/2072-6694/14/3/679  |x Verlag  |z lizenzpflichtig  |3 Volltext 
951 |a AR 
992 |a 20220406 
993 |a Article 
994 |a 2022 
998 |g 1012877264  |a Pajtler, Kristian Wilfried  |m 1012877264:Pajtler, Kristian Wilfried  |d 910000  |d 910500  |d 50000  |e 910000PP1012877264  |e 910500PP1012877264  |e 50000PP1012877264  |k 0/910000/  |k 1/910000/910500/  |k 0/50000/  |p 4  |y j 
998 |g 1038311837  |a Milde, Till  |m 1038311837:Milde, Till  |d 910000  |d 910500  |d 50000  |e 910000PM1038311837  |e 910500PM1038311837  |e 50000PM1038311837  |k 0/910000/  |k 1/910000/910500/  |k 0/50000/  |p 3 
998 |g 1209581906  |a Ghasemi, David R.  |m 1209581906:Ghasemi, David R.  |p 1  |x j 
999 |a KXP-PPN1797754092  |e 4112490208 
BIB |a Y 
SER |a journal 
JSO |a {"type":{"media":"Online-Ressource","bibl":"article-journal"},"id":{"eki":["1797754092"],"doi":["10.3390/cancers14030679"]},"recId":"1797754092","origin":[{"dateIssuedDisp":"28 January 2022","dateIssuedKey":"2022"}],"name":{"displayForm":["David R. Ghasemi, Gudrun Fleischhack, Till Milde and Kristian W. Pajtler"]},"language":["eng"],"note":["This article belongs to the Special issue: Medulloblastoma systemic therapy clinical trials and their foundations","Gesehen am 06.04.2022"],"person":[{"given":"David R.","display":"Ghasemi, David R.","family":"Ghasemi","role":"aut"},{"given":"Gudrun","display":"Fleischhack, Gudrun","role":"aut","family":"Fleischhack"},{"given":"Till","family":"Milde","role":"aut","display":"Milde, Till"},{"role":"aut","family":"Pajtler","display":"Pajtler, Kristian Wilfried","given":"Kristian Wilfried"}],"relHost":[{"physDesc":[{"extent":"Online-Ressource"}],"title":[{"title_sort":"Cancers","title":"Cancers"}],"part":{"pages":"1-22","year":"2022","issue":"3","extent":"22","text":"14(2022), 3, Special issue, Artikel-ID 679, Seite 1-22","volume":"14"},"pubHistory":["1.2009 -"],"note":["Gesehen am 27.05.2020"],"language":["eng"],"disp":"The current landscape of targeted clinical trials in non-WNT/non-SHH medulloblastomaCancers","name":{"displayForm":["Molecular Diversity Preservation International (MDPI)"]},"origin":[{"publisher":"MDPI","publisherPlace":"Basel","dateIssuedKey":"2009","dateIssuedDisp":"2009-"}],"id":{"issn":["2072-6694"],"zdb":["2527080-1"],"eki":["614095670"]},"recId":"614095670","type":{"media":"Online-Ressource","bibl":"periodical"}}],"title":[{"title":"The current landscape of targeted clinical trials in non-WNT/non-SHH medulloblastoma","title_sort":"current landscape of targeted clinical trials in non-WNT/non-SHH medulloblastoma"}],"physDesc":[{"extent":"22 S."}]} 
SRT |a GHASEMIDAVCURRENTLAN2820